
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Sanprobi | National Science Centre, Poland
Deal Size : Inapplicable
Deal Type : Inapplicable
Anti-inflammatory Probiotics in Cognitive Functioning
Details : Bifidobacterium Longum is a Probiotic drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
September 10, 2025
Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Sanprobi | National Science Centre, Poland
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy Adults
Details : B. Longum is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bifidobacterium Longum is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
September 23, 2021
Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials | CREMO SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bifidobacterium Longum is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 01, 2019
Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials | CREMO SA
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome
Details : Bifidobacterium Longum is a Probiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
January 13, 2011
Lead Product(s) : Bifidobacterium Longum
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All